Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti CD19 engineered antibody for target conjugated lymphocyte, leuco cyte and its use

A technology of leukemia cells and lymphocytes, applied in the field of engineering antibodies, can solve problems such as inability to calculate long-term survival rate, poor curative effect, and short survival period

Inactive Publication Date: 2006-05-24
INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chemotherapy is currently the main treatment for adult ALL, but the curative effect is poor. Although temporary remission can be achieved, the survival period is short
The curative effect of adult ALL in my country is even worse, so that its long-term survival rate cannot be calculated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti CD19 engineered antibody for target conjugated lymphocyte, leuco cyte and its use
  • Anti CD19 engineered antibody for target conjugated lymphocyte, leuco cyte and its use
  • Anti CD19 engineered antibody for target conjugated lymphocyte, leuco cyte and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] The anti-CD19 engineering antibody used for targeting lymphocytic leukemia cells of the present invention will be further described in detail in conjunction with the accompanying drawings and specific embodiments:

[0028] HI19a is a mouse anti-human CD19 monoclonal antibody hybridoma cell line developed by the Institute of Hematology, Chinese Academy of Medical Sciences with independent intellectual property rights. The anti-CD19 monoclonal antibody secreted by this cell line recognizes a 95KDI-type transmembrane glycoprotein. Almost all B-ALL leukemia cells express CD19 surface antigen.

[0029] The heavy chain and light chain variable region (VH, VL) genes of the antibody were cloned from the anti-CD19 monoclonal antibody hybridoma cell HI19a by RT-PCR method, and the cloned genes were 366bp (SEQID NO.1) and 324bp in length respectively (SEQ ID NO.2), there is no stop codon in the gene, and it is an open reading frame, encoding 122 (SEQ ID NO.3) and 108 (SEQ ID NO.4)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-CD19 engineering antibody and its application which is used in target direction combining lymphocytic leukemia cell. It lays a foundation for the next trituration genetic engineering medicine of the target direction therapy leukemia. It relates to anti-CD19 monoclonal antibody HI19a heavy and light chain variable region gene, and application of the gene code polypeptide, the gene carrier, and using the gene and polypeptide to make leukemia therapy medicine. The heavy and light chain variable region gene is come from the anti-CD19 monoclonal antibody HI19a. The invention successfully adopts gene engineering technique to make anti-CD19 gene engineering antibody, and lays a foundation for the target direction therapy of the leukemia.

Description

technical field [0001] The invention relates to an engineering antibody, especially an anti-CD19 engineering antibody for targeting and binding to lymphocytic leukemia cells and its application. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a subtype of leukemia, mainly B-cell ALL (B-ALL), accounting for 70-80% of ALL, and the annual new incidence rate is 0.98 / 100,000 people. Chemotherapy is the main treatment for adult ALL at present, but the curative effect is poor. Although temporary remission can be achieved, the survival period is short. The curative effect of adult ALL in my country is even worse, so that the long-term survival rate cannot be calculated. Therefore, reducing the fatality rate of leukemia and developing and improving the treatment of leukemia is a focus of world medicine. [0003] With the development of modern molecular biology and immunology, the birth of genetically engineered antibodies has brought hope for the diagnosis and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K39/395A61P35/00
Inventor 王敏王建祥陈森廖小龙饶青邢海燕田征唐克晶林冬
Owner INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com